Insights

  • Date

  • Content Type

  • Reset

Blog

How to manage the risk of foreign visible particles in ATMPs

22.10.20

By Elena Meurer and Noemi Lupo

Being free of visible particles is a must for parenteral products. However, occurrence of visible particles in ATMPs...

Read More

Blog

The art of giving advice – why and how great consultants make a real difference!

20.08.20

By Timo Liebig

Drug development is an extremely complex endeavor and a plethora of interdisciplinary skills is required to successfully develop...

Read More

Blog

How far are we with the accelerated development of SARS-CoV-2 vaccines – a review and outlook

13.08.20

By Noemi Lupo and Michael Pfleiderer

Development of SARS-CoV-2 vaccine comes with an unprecedented number of challenges ranging from CMC to clinical development. This...

Read More

Blog

Navigating the maze of environmental risk assessments for genetically modified products including ATMPs/CGTs

5.08.20

By Jörg Schneider


Environmental risk assessments (ERAs) for medicines containing genetically modified products are a prerequisite for clinical trial applications and...

Read More

Blog

Essential safety considerations for cell and gene therapies

3.07.20

By David Koziel

Cell and gene therapies offer novel approaches for many still unmet medical needs, like severe inherited and acquired...

Read More

Blog

Unravelling the regulatory riddle for exosome-based therapies

16.06.20

By Nermina Vejzagic

Exosomes are nanosized extracellular vesicles emerging as a new therapeutic platform.Development and regulation of exosome pose a challenge...

Read More

We are now Cencora PharmaLex 

PharmaLex is now part of Cencora, a leading global healthcare company with a foundation in pharmaceutical distribution. In 2024 and beyond PharmaLex and all the companies in PharmaLex family will begin a journey to becoming Cencora as well. Cencora brings the companies and services together under one new name. The name will change, but the level of attention and service you receive remains the same.  

Know more